PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
All news - Pipelinereview
WEB4 days ago · LEHI, UT, USA I September 23, 2024 I Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced promising preclinical results from their investigational compound HT-6184, combined with the GLP-1 agonist semaglutide. The study revealed significant weight loss in a diet-induced obesity (DIO) mouse ...
Small Molecules - Pipelinereview
WEBSep 15, 2024 · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Kashiv BioSciences Enters into Exclusive Licensing Agreement with ...
WEBJul 1, 2024 · Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ®). ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III
Biohaven Achieves Positive Topline Results in Pivotal Study of ...
WEB4 days ago · NEW HAVEN, CT, USA I September 23, 2024 I Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of ...
Monte Rosa Therapeutics Announces Initiation of IND Enabling …
WEBMar 11, 2024 · MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome. MRT-8102 and other NEK7 program MGDs are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological diseases
Pinetree Therapeutics Announces Exclusive Option and Global …
WEBJul 24, 2024 · Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over $500 million including potential additional development and commercial milestone payments
Telix to Acquire RLS to Expand North American Manufacturing and ...
WEB4 days ago · MELBOURNE, Australia, INDIANAPOLIS,IN and LAKE MARY, FL, USA I September 23, 2024 I Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET [1], SPECT [2] and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS …
Lilly and Innovent Biologics Expand Their Strategic Alliance to …
WEBOct 12, 2015 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the …
WEBSep 16, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Skip to content